C-peptide induces human renal mesangial cell proliferation in vitro, activating Src-kinase, PI-3 kinase and ERK1/2

Molecular and Cellular Endocrinology

Volumn 351, Issue 2, 2012, Pages 337-341

  Vasic, Dusica ^a   Spyrantis, Andreas ^a   Durst, Renate ^a   Bach, Helga ^a   Vogt, Sonja ^a   Rottbauer, Wolfgang ^a   Walcher, Daniel ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

C peptide; Diabetic nephropathy; Mesangial cell proliferation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; C PEPTIDE; CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; THYMIDINE; TRITIUM; U 126; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

BUTADIENES; C-PEPTIDE; CELL PROLIFERATION; CELLS, CULTURED; CHROMONES; CYCLIN D1; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLOMERULAR MESANGIUM; HUMANS; MAP KINASE SIGNALING SYSTEM; MESANGIAL CELLS; MORPHOLINES; NITRILES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PYRIMIDINES; RETINOBLASTOMA PROTEIN; SRC-FAMILY KINASES;

EID: 84857140448     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.01.011     Document Type: Article

References (30)

1. Aleksic M., Walcher D., Giehl K., Bach H., Grüb M., Durst R., Hombach V., Marx N. Signaling processes involved in C-peptide-induced chemotaxis of CD4-positive lymphocytes. Cell Mol. Life Sci. 2009, 66:1974-1984.
2. Grande M.T., López-Novoa J.M. Therapeutical relevance of MAP-kinase inhibitors in renal diseases: current knowledge and future clinical perspectives. Curr. Med. Chem. 2008, 15:2054-2070.
3. Hadi H.A., Suwaidi J.A. Endothelial dysfunction in diabetes mellitus. Vasc. Health Risk Manag. 2007, 3:853-876.
4. Haupt, E., Benecke, A., Haupt, A., Herrmann, R., Vogel, H., Walter, C., 1999. The KID Study VI: Diabetic complications and associated diseases in younger type 2 diabetics still performing a profession. Prevalence and correlation with duration of diabetic state, BMI and C-peptide. Exp. Clin. Endocrinol. Diabetes 107, 435-441.
5. Inukai T., Matsutomo R., Tayama K., Aso Y., Takemura Y. Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type-2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 1999, 107:40-45.
6. Johansson B.L., Kernell A., Sjoberg S., Wahren J. Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J. Clin. Endocrinol. Metab. 1993, 77:976-981.
7. Joshua I.G., Zhang Q., Falcone J.C., Bratcher A.P., Rodriguez W.E., Tyagi S.C. Mechanisms of endothelial dysfunction with development of type 1 diabetes mellitus: role of insulin and C-peptide. J. Cell Biochem. 2005, 96:1149-1156.
8. Karalliedde, J., Viberti, G., 2010. Proteinuria in diabetes: bystander or pathway to cardiorenal disease? J Am Soc Nephrol. 21, 2020-2027.
9. Kato J., Matsushime H., Hiebert S.W., Ewen M.E., Sherr C.J. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes. Dev. 1993, 7:331-342.
10. Kitamura T., Kimura K., Jung B.D., Makondo K., Okamoto S., Cañas X., Sakane N., Yoshida T., Saito M. Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein. Biochem. J. 2001, 355:123-129.
11. Marx N., Walcher D., Raichle C., Aleksic M., Bach H., Grub M., Hombach V., Libby P., Zieske A., Homma S., Strong J. C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler. Thromb. Vasc. Biol. 2004, 24:540-545.
12. Mavrakanas T., Frachebois C., Soualah A., Aloui F., Julier I., Bastide D. C-peptide and chronic complications in patients with type-2 diabetes and the metabolic syndrome. Presse Med. 2009, 38:1399-1440.
13. Nordquist L., Moe E., Sjoquist M. The C-peptide fragment EVARQ reduces glomerular hyperfiltration in streptozotocin-induced diabetic rats. Diabetes Metab. Res. Rev. 2007, 23:400-405.
14. Nordquist L., Wahren J. C-peptide the missing link in diabetic nephropathy?. Rev. Diabet. Stud. 2009, 6:203-210.
15. +-ATPase activity of renal tubule segments. Diabetologia 1998, 41:287-291.
16. Rigler R., Pramanik A., Jonasson P., Kratz G., Jansson O.T., Nygren P., Stâhl S., Ekberg K., Johansson B., Uhlén M., Jörnvall H., Wahren J. Specific binding of proinsulin C-peptide to human cell membranes. Proc. Natl. Acad. Sci. USA 1999, 96:13318-13323.
17. Ruilope L., Izzo J., Haller H., Waeber B., Oparil S., Weber M., Bakris G., Sowers J. Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?. J. Clin. Hypertens. 2010, 12:422-430.
18. Samnegård, B., Jacobson, S.H., Jaremko, G., Johansson, B.L., Sjöquist, M. 2001. Effects of C-peptide on glomerular and renal size and renal function in diabetic rats. Kidney International 1258-1265.
19. Samnegård B., Jacobson S.H., Johansson B.L., Ekberg K., Isaksson B., Wahren J., Sjöquist M. C-peptide and captopril are equally effective in lowering glomerular hyperfiltration in diabetic rats. Nephrol. Dial. Transplant. 2004, 19:1385-1391.
20. Sari R., Balci M.K. Relationship between C-peptide and chronic complications in type-2 diabetes mellitus. J. Natl. Med. Assoc. 2005, 97:1113-1118.
21. Sima A.A., Zhang W., Grunberger G. Type 1 diabetic neuropathy and C-peptide. Exp. Diabesity Res. 2004, 5:65-77.
22. Stridh S., Sällström J., Fridén M., Hansell P., Nordquist L., Palm F. C-peptide normalizes glomerular filtration rate in hyperfiltrating streptozotocin-induced diabetic rats. In vivo measurements in conscious rats. Adv. Exp. Med. Biol. 2009, 645:219-225.
23. Vasic, D., Marx, N., Sukhova, G., Bach, H., Durst, R., Grüb, M., Hausauer, A., Hombach, V., Walcher, D., 2011. C-peptide promotes lesion development in a mouse model of arteriosclerosis, J. Cell. Mol. Med. 24, doi:. doi:10.1111/j.1582-4934.2011.01365.x.
24. Wahren J. C-peptide: new findings and therapeutic implications in diabetes. Clin. Physiol. Funct. Imaging 2004, 24:180-189.
25. Wahren J., Ekberg K., Johansson J., Henriksson M., Pramanik A., Johansson B.L., Rigler R., Jörnvall H. Role of C-peptide in human physiology. Am. J. Physiol. Endocrinol. Metab. 2000, 278:759-768.
26. Wahren J., Ekberg K., Jörnvall H. C-peptide is a bioactive peptide. Diabetologia 2007, 50:503-509.
27. Walcher D., Babiak C., Poletek P., Rosenkranz S., Bach H., Betz S., Durst R., Grüb M., Hombach V., Strong J., Marx N. C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2. Circ. Res. 2006, 99:1181-1187.
28. Walcher D., Marx N. C-peptide in the vessel wall. Rev. Diabet. Stud. 2009, 6:180-186.
29. Wolf G. Cell cycle regulation in diabetic nephropathy. Kidney Int. 2000, 77:59-66.
30. +-ATPase via activation of ERK1/2 MAP kinases in human renal tubular cells. Cell Mol. Life Sci. 2004, 61:2782-2790.